Ciclopirox Topical Solution Recalled Due to Manufacturing Practice Violations
Ciclopirox 8% topical solution (nail lacquer) is recalled nationwide. The manufacturer went out of business and could not complete required stability testing to ensure product safety.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving CGMP deviations (incomplete stability studies). No illnesses or injuries are reported. The inability to complete stability testing represents a risk-of-harm situation where product safety cannot be verified, meeting the criterion for High severity.
Plain-English summary
Akorn, Inc. is recalling all lots of Ciclopirox Topical Solution 8% (Nail Lacquer), 6.6 mL bottles, distributed nationwide in the United States and Puerto Rico.
The FDA classified this as a Class II recall due to Current Good Manufacturing Practice (CGMP) deviations. The recalling firm went out of business and could no longer continue the stability studies required for this medication.
Consumers currently using this product should contact their healthcare provider for guidance.
The recalled product
- Product
- Ciclopirox Topical Solution 8% (Nail Lacquer), 6.6 mL bottles, Rx Only, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical Antifungal
- Hazard
- cgmp-deviation
- stability-testing-incomplete
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27